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Abstract 
INTRODUCTION: The infection by HIV is a global pandemic. It is rapidly becoming a 
chronic disease whose course in the long term is very much unpredictable. In an era where 
disease progression is generally manageable, cardiovascular complications are an important 
cause of morbidity and mortality in HIV-positive children. The infection itself and the use of 
antiretroviral therapy are associated with increased risk of cardiovascular disease. 
OBJECTIVES: To present the state of the art in the various aspects of increased 
cardiovascular risk in HIV-infected paediatric community. The risk inflicted by both the 
infection itself and the currently used antiretroviral therapy on the cardiac and vascular 
systems will be presented.  
DISCUSSION: HIV infection has been shown to affect the heart and vascular system as 
early as during childhood. Infected children present with alterations of all layers of the heart. 
Structural and functional myocardial alterations have been identified as most prevalent, but 
pericardial effusion and endocarditis have also been reported. Vascular risk usually 
manifests later in life, with increased incidence of atherosclerotic disease. Biomarkers 
including increased intima-media thickness and decreased flow-mediated dilation are good 
indicators of increased risk even in earlier ages. The underlying mechanisms of increased 
cardiovascular risk are still under study and distinguishing between risk inflicted by the 
infection from risk inflicted by antiretroviral therapy is challenging.  
CONCLUSION: HIV infection in children may significantly affect the cardiovascular system. 
As HIV-positive children have added cardiovascular risk, control of traditional cardiovascular 
risk factors and monitoring of both cardiovascular and metabolic systems are of extreme 
importance. More in-depth paediatric research, which accounts for the interaction between 
normal growth and development, HIV infection and therapy, is fundamental. 
KEYWORDS: human immunodeficiency virus, HIV, cardiovascular risk, heart, vasculature, 
metabolic syndrome, atherosclerosis, children 
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Resumo 
INTRODUÇÃO: A infeção pelo HIV é uma pandemia global. Está rapidamente a tornar-se 
uma doença crónica cuja evolução a longo prazo é, em muitos aspetos imprevisível. Numa 
era em que a progressão da doença é em geral controlável, as complicações 
cardiovasculares são importante causa de morbilidade e mortalidade em crianças HIV-
positivas. A infeção em si e o uso de terapia antirretroviral estão associados a risco 
cardiovascular aumentado. 
OBJETIVOS: Apresentar o estado da arte nos vários aspetos de risco cardiovascular 
aumentado na comunidade pediátrica HIV-infetada. O risco inferido nos sistemas cardíaco e 
vascular, pela infeção em si e pela terapia antirretroviral atualmente utilizada serão 
apresentados. 
DESENVOLVIMENTO: Foi demonstrado que a infeção pelo HIV afeta o coração e o 
sistema vascular tão precocemente como durante a infância. Crianças afetadas apresentam 
alterações de todas as camadas do coração. Alterações estruturais e funcionais 
miocárdicas foram identificadas como sendo as mais prevalentes, mas derrame pericárdico 
e endocardite foram também relatadas. Risco vascular habitualmente manifesta-se mais 
tardiamente por um aumento na incidência de doença aterosclerótica. Biomarcadores como 
a espessura intima-media aumentada e dilatação fluxo-mediada diminuída são bons 
indicadores de risco aumentado mesmo em idades mais precoces. Os mecanismos 
inerentes ao risco cardiovascular aumentado estão ainda a ser estudados e a distinção 
entre o risco relacionado com a infeção e o risco relacionado com a terapia antirretrovírica é 
desafiante. 
CONCLUSÃO: A infeção pelo HIV nas crianças pode afetar significativamente o sistema 
cardiovascular. Dado que as crianças HIV-positivas têm risco cardiovascular acrescido, o 
controlo dos fatores de risco cardiovascular tradicionais e a monitorização dos sistemas 
cardiovascular e metabólico são de extrema importância. Investigação na área pediátrica, 
tendo em conta a interação entre o crescimento e desenvolvimento normal, a infeção pelo 
HIV e a terapia é fundamental. 
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1. Introduction 
The infection by the Human Immunodeficiency Virus (HIV) is a global pandemic. The first 
case was reported in the United States of America in 1981. Since then the epidemic has 
been on-going for the last three decades, affecting an increasing amount of individuals. As 
of 2015, it is estimated that a total of 36.7 million people are living with HIV, including 2.6 
million children under the age of fifteen (UNAIDS, 2016). Whilst its incidence seems to be 
decreasing in the past years, HIV is rapidly becoming a chronic disease whose course in the 
long term is very much unpredictable. HIV infection in paediatric ages is mainly acquired 
through mother-to-child transmission, either during delivery or through breastfeeding. New 
infections in adolescents are mainly acquired horizontally by means of sexual intercourse, or 
intravenous drug use. The infected paediatric population seems to be decreasing, given that 
proper viral load control in pregnant women and the use of prophylactic measures have 
decreased the risk of mother-to-child transmission (NIH, 2016). 
The discovery of Highly Active Retroviral Therapy (HAART) was a tremendous breakthrough 
in medical history and since its first introduction in 1996, HAART has been the main pillar in 
the treatment of HIV-positive patients. It has been largely responsible for a decline in 
morbidity and mortality in these patients. It is estimated that > 50% of HIV-positive persons 
will be > 50 years of age as of 2015, as a result of successful virological management (CDC, 
2011). This changing epidemiological panorama presents a scenery of complications which 
were previously unknown and an added responsibility to evaluate the long-term effects of 
the disease on overall health.  
One of the main complications of HIV infection currently acknowledged is cardiovascular 
(CV) disease. In an era where disease progression is generally manageable, cardiovascular 
complications are an important cause of morbidity and mortality in HIV-positive patients. The 
aging pattern of the HIV-infected population has led to an increased prevalence of traditional 
CV risk factors such as hypertension, diabetes, dyslipidaemia and smoking. HIV infection is 
also an independent risk factor for CV disease. The infection itself and the use of HAART 
are associated with increased risk of CV disease.  
HIV can affect the heart and vasculature in multiple ways, both in short and long-term. 
Structural and functional disruptions can develop due to HIV infection and treatment and, to 
this day some manifestations are associated mainly to the disease itself, others to the use of 
HAART and some remain in a grey area where the mechanism of disease is yet to be 
determined or believed to be largely multifactorial. The effect of HIV and its therapy on 
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traditional CV risk factors is also relevant.  A number of metabolic alterations are more 
prevalent in HIV-positive individuals, including insulin resistance, diabetes and 
dyslipidaemia. Smoking, interestingly enough, seems to have a higher prevalence in HIV-
positive individuals when compared to HIV-negative individuals (Cerrato E, 2015).  
It seems that, in adults, these alterations express themselves as a higher risk for 
atherosclerosis, cardiovascular events and heart failure. In children, the most immediate 
clinical presentations involve the heart whilst long term CV risk seems to be largely related 
to vasculature damage and its consequences. As HIV-positive children are expected to live 
longer with the disease than the an individual who is infected as an adult, measures of CV 
risk in this population become extremely relevant. 
In this review article, I aim to assembly the current knowledge of CV risk in the paediatric 
population affected by HIV infection. An attempt at differentiating between infection-related 
and therapy-related alterations on the CV system will be made. All research was conducted 
using the PubMed database and only articles from the year 2000 onwards were accepted. A 
broad search on general cardiovascular risk was then refined to more specific areas of 
concern. Initially research was focused only on Paediatrics-related articles, but it was later 
on expanded to adults on topics where there was limited evidence for children. Given the 
relative difficulty in finding material on certain areas, bibliographies of retrieved articles were 
also considered to obtain additional information. A total of seventy articles were used as the 
final bibliography. 
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2. Paediatric HIV Infection and the Heart 
 
HIV infection is a primary cause of acquired heart disease. All layers of the heart may 
be affected – endocardium, myocardium and pericardium – and manifestations seem 
to differ in a developed and in a developing heart. Structural and functional damage 
are, of course, many times correlated as one usually leads to the other. As disease 
of the pulmonary artery can correlate to heart dysfunction, this topic will be discussed 
in the current section. Before HAART was implemented, subclinical cardiac 
abnormalities in early childhood were extremely prevalent and these tended to 
progress to clinical disease within a few years (Orav EJ, 2002). Up to 25% of HIV-
infected children presented with CV disease early in life, with serious cardiac events 
typically occurring between eight months and five years of age (Al-Attar I, 2003).  In 
the P2C2 HIV longitudinal study of vertically HIV-infected children before HAART use, 
cardiac mortality was 35% (Al-Attar I, 2003). In children, as in adults with HIV 
infection, cardiac morbidity and mortality were associated with more advanced 
disease and with coinfections (Mas CM, 2012). The most common CV manifestations 
were myocardial disease, pericardial effusions, pulmonary hypertension and rhythm 
disturbances.   
The panorama of heart manifestations has changed since the introduction of HAART. 
There is good evidence that HAART regimens significantly reduce the incidence of 
heart disease in HIV-infected children, even though some of the drugs used are by 
themselves cardiotoxic.  
 
2.1. Endocardium Injury 
Infective endocarditis and nonbacterial thrombotic endocarditis are some possible 
complications of HIV infection when it comes to the endocardium. These seem to be 
somewhat prevalent in the adult population but very rare in HIV-infected children 
(Fisher SD, 2011).  
 
 
2.2. Myocardium Injury 
The exact pathogenesis of heart structural and functional damage is still greatly 
unknown. Most studies on underlying mechanisms were done in adults but it is 
believed that these can be applied to the paediatric community as well. Although 
each type of cardiac pathology may have specific causes, general effects on 
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children’s hearts may occur through HIV-induced inflammatory mediators, such as 
cytokines and proteolytic enzymes, co-infection, nutritional deficiencies, autoimmune 
response to infecting pathogens, HAART cardiotoxicity and/or direct viral cell 
invasion (Merchant RH, 2012). Most researchers suggest a multifactorial aetiology 
(Brown SC, 2005).  Studies of heart tissue have demonstrated that direct HIV 
infection of cardiomyocytes is rare, which suggests that indirect mechanisms 
predominate (Currie PF, 2003). 
Dilated cardiomyopathy is more common in HIV-infected children and increases in 
frequency as the disease progresses. It carries a much worse prognosis than 
idiopathic dilated cardiomyopathy (Merchant RH, 2012). 
Myocardial disease confers poor prognosis by itself as it results in symptomatic heart 
failure in up to 5-10% of HIV-infected children (Singh P, 2015). 
Myocarditis is probably the most important cause of HIV-associated cardiomyopathy. 
A number of pathogenic routes have been discussed, including direct action of HIV 
on myocardial tissue, action of proteolytic enzymes or cytokine mediators induced by 
HIV alone or with co-infecting viruses (Pozzan G, 2009). Various pathogens have 
been found on HIV-infected patients, using endomyocardial biopsy. Some examples 
are cytomegalovirus, mycobacteria sp., toxoplasma, Candida sp., histoplasma and 
Staphylococcus aureus; however, the clinical significance of these findings is still 
unclear (Barbaro G, 2001). It is important to note that only scant and patchy 
inflammatory cell infiltrates and necrosis in the myocardium have been identified on 
autopsy and biopsy, suggesting that secondary infection is unlikely to cause 
myocarditis directly. The fact that, in adults, only PCR can identify these opportunistic 
pathogens indicates that pathogen load is low and supports the previous statement. 
A potentially important route of cardiomyocyte cell damage is through increased 
TNF-α production induced by HIV infection. Reservoir cells located in myocardial and 
brain interstitial tissue may harbour viruses for extended periods and chronically 
release cytotoxic cytokines, including TNF-α, IL-6, IL-1, TGF-β (Barbaro G, 2001). 
This cytokine release results in tissue damage. TNF-α alters intracellular calcium 
homeostasis and induces nitric oxide synthesis, which can injure myocardial cells 
and produce negative inotropic effects as a consequence. TNF-α induced apoptosis 
and myocardial diffuse regressive alterations have been observed in HIV-infected 
patients with biventricular dilation (Yearley JH, 2008).  
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Nutritional deficiencies are prevalent in HIV-infected individuals, particularly in the 
late stages and in young infants. Electrolyte imbalances and deficiencies in 
elemental nutrients usually result from poor intake, malabsorption and diarrhoea.  
Deficiency of trace elements, especially selenium, may be linked to cardiomyopathy 
in HIV uninfected children and this may be relevant in HIV-infected children 
(Longenecker C, 2012). Low levels of vitamin B12, carnitine, growth hormone and 
thyroid hormone may occur in HIV infection, and are also associated with left 
ventricle (LV) dysfunction (Miller TL, 2013).  A lower body mass index is an 
independent risk factor for cardiomyopathy (Lemmer CE, 2011). 
There are two types of HIV-associated cardiomyopathy: LV dilation with a reduced 
ratio of LV wall thickness to end-systolic dimension, and dilation with concentric 
hypertrophy, such that the ratio of wall thickness to end-systolic dimension is 
unchanged or increased (Easley KA, 2000). These may be manifested as LV systolic 
dysfunction, which can be clinically ranges from asymptomatic to symptomatic heart 
failure, and probably diastolic dysfunction (Miller TL, 2013).  
 
 
Figure	  1	  -­‐	  Mechanism	  of	  cardiac	  damage	  induced	  by	  HIV	  reservoir	  cells.	  Retrieved	  from	  Barbaro	  G,	  2001.	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2.2.1. Left Ventricular Systolic Dysfunction 
Before HAART, the two-to-five year incidence of symptomatic heart failure ranged 
from 4 to 28% in HIV patients, suggesting a prevalence of symptomatic HIV-related 
heart failure of between 4 and 5 million cases worldwide (Easley KA, 2000).  
As far as clinical presentation, patients can present with LV systolic dysfunction that 
is anywhere from asymptomatic to NYHA Class IV heart failure, with severe 
functional limitations (Mas CM, 2012).  Echocardiography with strain measurements 
may be useful in assessing LV function, allowing for the diagnosis of LV dysfunction. 
Some of the possible findings are LV hypertrophy, dilation or low-to-normal wall 
thickness, as well as atrial dilation. Progressive LV dilation is quite prevalent among 
HIV-infected children and it may precede heart failure. This finding is associated with 
elevated LV afterload, LV hypertrophy and reduced LV function (Williams PL, 2013). 
Cardiomegaly could be identified in more than half of HIV-infected children and was 
associated with increased LV mass, symptomatic disease and pericardial effusion 
(Kearny DL, 2003). Echocardiographic evaluation should be performed at diagnosis 
and every 1-2 years thereafter. In selected patients, with higher CV risk or evidence 
of CV disease, these recommendations should be adjusted (Mondy KE, 2011). 
Electrocardiography (ECG) commonly shows nonspecific conduction defects or 
repolarization defects in HAART naïve patients. A number of studies have also 
shown an inverse correlation between blood natriuretic peptide concentrations and 
LV ejection fraction (Wilkinson JD, 2013).  
In the pre-HAART era, median survival from diagnosis to an AIDS-related death was 
101 days in patients with LV dysfunction. This data can be compared with an 
estimated time median survival of 472 days in patients without cardiac dysfunction 
and at a similar stage of HIV disease (Easley KA, 2000). 
HAART seems to have a cardioprotective effect and to prevent LV dysfunction.  
Whether it does so directly, by reducing HIV-related cardiac damage, or indirectly, 
through improving overall health and nutritional status, is still not clarified (Williams 
PL, 2013).  Patients receiving therapy still frequently show some asymptomatic 
abnormalities in cardiac structure. The hearts of children treated with multidrug 
antiretroviral therapy (ART) have less LV mass and smaller chambers but greater 
function. This increase in function may be a compensation of the smaller LV size. 
These children showed higher LV contractility than HAART-unexposed children, 
which resulted in such alterations being subclinical (Mas CM, 2012). 
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Echocardiographic studies have identified that around 18% of HAART treated 
patients have LV dysfunction, 6.5% have LV hypertrophy and 40% have left atrial 
dilation (Mondy KE, 2011). Left ventricular systolic dysfunction may be subtle with 
prolonged HAART duration (>10 years) and only detectable by strain 
echocardiography that measures myocardial deformation in circumferential, radial 
and longitudinal directions (Frank L, 2012). HIV-infected children and young adults 
may have impaired longitudinal strain and strain rate despite normal systolic function 
and ejection fraction (Al-Naami G, 2014). Among HAART-treated children, older age 
at treatment initiation, a regimen containing zidovudine, and a nadir CD4 %<15% 
were independent predictors of cardiomyopathy (Patel K, 2012) Although HAART 
exposure may be cardioprotective, this is only true for a finite period early in life. This 
effect decreases as the HIV-infected population ages into adolescence and early 
adulthood (Orav EJ, 2002). It is possible that HAART may block myocardial 
hypertrophy and hyperplasia and reduce myocardial energy production; increase 
cardiac apoptosis and block repair mechanisms as a result of mitochondrial toxicity 
(Mas CM, 2012).  
Studies have suggested that any cardiac changes in the HAART era are generally 
subclinical in children. Further, in addition to characterizing lifetime HAART 
exposure, traditional non-HIV CV risk factors will be needed to best determine 
differences in global CV risk between perinatally HIV-infected children and the 
general population (Miller TL, 2013).   
 
2.2.2. Left Ventricular Diastolic Dysfunction 
Echocardiographic and clinical data have shown that diastolic cardiac dysfunction is 
relatively common in long-term survivors of HIV infection. In adults, an independent 
association between diastolic dysfunction and HIV infection was reported in a series 
of studies, even among asymptomatic HIV-infected patients in the early stages of the 
disease (Aggarwal P, 2009). Nearly 50% of HIV-infected, particularly older 
individuals with higher blood pressure and heart rate (both HAART naïve and 
exposed) have mild diastolic dysfunction.  After adjustment for age and hypertension, 
HIV infected adults still present a 2.4-fold increased risk for diastolic dysfunction 
compared with uninfected subjects (Hsue PY, 2010). 
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LV diastolic dysfunction can be the first sign of underlying cardiac disease and it may 
precede LV systolic dysfunction (Reinsch N, 2010). LV compliance decreases as LV 
diastolic dysfunction worsens and left atrial pressure increases. Moderate to severe 
LV diastolic dysfunction independently predicts mortality, regardless of normal LV 
systolic function (O'Brien S, 2011). Whether LV diastolic dysfunction is associated 
with an increased risk of early coronary disease is unknown (Nayak G, 2009). 
The physiopathology behind the diastolic dysfunction on these patients is not clear 
yet. It is postulated that it might result from HIV infection itself, HAART and/or other 
comorbidities. Although more studies are needed on this topic, it was noticeable that 
affected subjects tended to have lower CD4 count and/or a longer duration of 
treatment with nucleoside reverse transcriptase inhibitors (NRTIs) (Hsue PY, 2010).  
Data on the paediatric population is even scanter. Left or right ventricular diastolic 
dysfunctions, predominantly of the restrictive pattern, were found in roughly 40 and 
30% respectively on clinically stable HIV-positive children (Silva ML, 2014). Other 
reports on left ventricular diastolic dysfunction in children are again limited, and the 
existing are almost always associated with systolic dysfunction, as these patients are 
usually symptomatic (Silva ML, 2014).  The relationship between LV diastolic 
dysfunction and HIV treatment status has not been clearly demonstrated, but HAART 
may play a role as HIV-exposed but uninfected infants who have been exposed to 
prophylactic HAART have lower early diastolic annular velocity than controls (Cade 
WT, 2012). Future echocardiographic studies on the temporal occurrence of LV 
systolic versus diastolic changes may be important in determining the effects of HIV 
exposure and HAART exposure (Silva ML, 2014). 
 
2.3. Pericardium Injury 
Pericardial effusion was a major concern in the pre-HAART era, with up to 11% of 
HIV-positive patients presenting with this complication (Lindl A, 2011). Current data 
indicates that the prevalence in developed countries with easy access to ART has, in 
fact, very much decreased whilst it still accounts for around 12% of cardiac 
manifestations in African countries (Brown SC, 2005). 
Generally, effusions are small and asymptomatic and drainage is rarely required but 
close monitoring is mandatory to detect possible opportunistic infections (Brown SC, 
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2005). Pericardiocentesis is indicated when there are clinical or echocardiographic 
signs of tamponade (Miller TL, 2013). Pericardial effusion is often part of a complex 
and generalized effusive process, usually involving pleural and peritoneal surfaces. It 
is believed that the pathogenesis behind it has to do with enhanced cytokine 
production associated with HIV infection, which leads to “capillary leakage” of serous 
fluid. Other related mechanisms include uraemia from HIV nephropathy or drug 
nephrotoxicity (Lindl A, 2011). There seems to be an association between pericardial 
effusion and tuberculosis infection in lower income countries, where it is highly 
prevalent (Brown SC, 2005). Children infected with HIV are at higher risk for 
tuberculosis (Matthews K, 2012).  
HIV patients with pericardial effusions tend to have lower CD4 counts than those 
without effusions and the risk of death in these patients nearly triples (McLaughlin 
VV, 2009) (Lindl A, 2011). 
 
2.4. Pulmonary Hypertension 
Data on the prevalence of pulmonary hypertension associated with HIV infection is 
mainly available for the adult population. About 0,5% to 5% of the adult HIV-positive 
community has developed pulmonary hypertension, with an apparent female 
predominance (Bloomfield GS, 2014). It is believed that this could possibly be an 
underestimation as most patients accountable in this prevalence data are 
symptomatic, with asymptomatic going unaccounted for (Mirrakhimov AE, 2013). The 
introduction of HAART hasn’t altered the prevalence of this pathology (Opravil M, 
2008). 
On autopsy reports, findings of pulmonary arterial hypertension seem to be a 
consequence of the replacement of normal endothelial structure by arteriopathic 
remodelling with intimal fibrosis (Cicalini S, 2011).  Although the pathogenic 
mechanisms behind these alterations are still largely in need of more studying, it is 
believed that it may involve HIV-related proteins (such as Gp-120 protein, Nef and 
Tat), HIV-induced inflammation, co-infections (particularly Human Herpes Virus 8, 
Hepatitis C and Hepatitis B) and heightened inflammation due to exposure of 
microbial products, thromboembolic events and genetic susceptibility through certain 
HLA subtypes (Cicalini S, 2011).  It is also possible that HAART influences the 
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pathogenesis and severity of the pulmonary hypertension, however, there is not 
enough data to evaluate this correlation (Bloomfield GS, 2014).  
The most common clinical presentation in these patients is dyspnoea and children 
may also present with signs of right-sided heart failure, such as facial oedema, 
hepatomegaly or oedema of the lower extremities. Upon evaluation, perfusion scans 
are usually normal (McLaughlin VV, 2009). Most adults show cardiomegaly, 
pulmonary arterial enlargement, dilated right ventricle and tricuspid regurgitation 
(Stewart D, 2011). In patients with HIV and pulmonary hypertension, pulmonary 
hypertension should be aggressively treated as it is life threatening. Most morbidity 
and mortality in these patients seem to be caused by pulmonary hypertension and, 
therefore, it should be clinically managed as a priority (McLaughlin VV, 2009). 
 
2.5. Rhythm Disturbances 
There seems to be a higher prevalence of electrocardiographic anomalies in HIV-
infected children, with 50 to 93% of these patients presenting with voltage 
disturbances, conduction defects and dysrhythmias, between other alterations.  
Some of the most frequent dysrhythmias noted are second-degree atrioventricular 
block and supraventricular or ventricular tachycardia (Saidi AS, 2000).  Most 
anomalies seem to be benign and without need to therapeutic action. 
QT prolongation is also associated with HIV infection and seems to affect children 
with increased frequency as they age (Saidi AS, 2000).  This alteration may 
predispose to torsades de pointes ventricular tachycardia (Miller TL, 2013). HAART 
may possibly be involved in the development of QT prolongation in HIV patients, 
particularly when in the use of protease inhibitors (PIs). The clinical significance of 
this finding is sill unclear (Hunt K, 2011).    
Patients are at risk for sudden cardiac death late in HIV infection, and it is becoming 
increasingly common as the HIV-infected population ages (Miller TL, 2013). This is 
normally related to autonomic nervous system disturbances such as attenuation of 
the parasympathetic-mediated circadian rhythm heart variability and impairment of 
night-time QTc interval lengthening. Cardiac autonomic dysfunction correlates with 
adverse immunological status of HIV-infected children (Benchimol-Barbosa PR, 
2009).  
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2.6. In Utero Development 
Mother-to-child transmitted HIV infection was in the past one of the main concerns of 
the paediatric community. The use of HAART prophylaxis on HIV-positive pregnant 
women reduced this transmission path rates from more than 20% to approximately 
8% (Mas CM, 2012).  As of its implementation, the prevalence of HIV infection 
acquired through mother-to-child transmitted in developed countries has been 
reduced to less than 2% (Mofenson LM, 2000). However, where there are many 
positive aspects of the use of this prophylaxis, there also seems exist another side of 
the coin. 
HIV can affect the developing heart both in utero, on a foetus of an HIV-positive 
mother, and after birth. Many approaches have come up on the issue of congenital 
anomalies of the heart related to HIV. Seemingly both HIV infection itself and HAART 
exposure are involved in this pathogenesis.  
Children who are born to HIV-positive mothers present with LV dysfunction with 
reduced contractility indices that may persist over time, irrespective of the HIV 
infection status of the infant. This was suggested to be a consequence of the uterine 
environment provided by the HIV-positive mother, which gives rise to important 
cardiovascular effects on the foetus (Orav EJ, 2002). Apart from exposure to HIV 
itself, many children are exposed to HAART in utero to prevent transmission of the 
virus. There seems to be a higher rate of congenital anomalies in infants exposed to 
antiretroviral agents during pregnancy than in unexposed infants (Knapp KM, 2012). 
Foetal and early neonatal HAART exposure was associated with substantially lower 
LV wall thickness and mass, as well as with impaired myocardial growth (Shearer 
WT, 2011). Studies have been conducted on specific drugs used in HAART 
regimens and the their relation to cardiac congenital alterations. Abacavir, nelfinavir, 
nevirapine and zidovudine were some of the implicated drugs. Abacavir seems to be 
associated with decreased LV dimension; nelfinavir exposure was related to lower 
aortic valve diameter and reduced LV wall thickness. Nevirapine increased risk of 
increased LV wall thickness (Lipshultz SE, 2010). It is still unknown exactly what are 
the clinical implications of these HAART-associated cardiac alterations, however they 
confirm the potential of any adverse effects of HAART to be independent of the 
confounding effects of HIV infection (Mas CM, 2012).  
HAART is a greater good in reducing the rates of mother-to-child HIV transmission, 
however, children exposed to HAART in utero, regardless of their HIV status, should 
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have long term cardiac follow up because even mild LV dysfunction increases 
premature cardiac mortality over time (Mas CM, 2012).  	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3. Paediatric HIV Infection and the Vasculature 
The relevance of the correlation between HIV infection and vascular disease is 
increasingly recognized. With the implementation of HAART, HIV-positive patients 
are living longer lives and the importance of chronic conditions such as 
atherosclerotic and metabolic diseases is growing as the population ages (Fitch K, 
2011).  A 1.5-1.7-fold increased risk for myocardial infarction (MI) has been noted in 
adults with HIV infection (Triant VA, 2007). Acute MI can be the primary presentation 
of atherosclerosis in these patients (Miller TL, 2013).  All in all, HIV infection, its 
therapies and cardiometabolic consequences have marked effects on the 
vasculature.  
The pathogenesis behind the increased atherosclerotic disease in these patients is 
related to the state of constant low-grade inflammation produced by the infection, 
correlated to the level of viral control (Maniar A, 2013). Another related mechanism is 
the co-existence of a metabolic syndrome in HIV patients. The syndrome is 
characterized by lipodystrophy (redistribution of fat with reduction in subcutaneous 
and increase in visceral fat), dyslipidaemia, insulin resistance and abnormal glucose 
metabolism (Grinspoon S, 2005). Both the HIV infection and the use of HAART, 
particularly the exposure to PIs and certain NRTIs, can be in the genesis of the 
syndrome (Miller TL, 2013).  This is a controversial topic as most data has been 
collected on the correlation between HAART and metabolic disease in HIV-positive 
patients, and not enough research has been done on the effect of HIV disease itself. 
In these studies, following exposure to HAART, there are increases in total, LDL, and 
HDL cholesterol in both adults and children (Miller TL, 2013). However, some data 
has shown that HIV-infection in adults may, in fact, independent of HAART exposure 
status be associated with dyslipidaemia, with high triglycerides and decreased HDL 
cholesterol (El-Sadr WM, 2005).  
The pathophysiology of accelerated atherosclerosis in HIV-infected patients is 
therefore complex. The mechanisms are probably different in HAART-naïve and 
exposed patients. It is believed that in HAART-naïve patients, the immune activation 
and chronic inflammatory state predominates. In these patients, early endothelial 
dysfunction is promoted by immune mediators and is maintained by HIV viral 
persistence, microbial translocation associated with mucosal barrier damage, and co-
infection (Baker JV, 2011). Additionally, normal vascular restoration after injury 
appears to be impaired in HIV infection.  Although HAART controls many of the 
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pathogenic pathways of HIV when it comes to atherosclerosis, mainly by controlling 
viral load, it is well known that HAART-exposed patients may still have a higher 
cardiovascular risk than the general population.  Chronic immune activation and 
inflammation may promote atherosclerosis and increased arterial stiffness in the 
absence of residual viral replication (Ross AC, 2009). In fact, HAART can have 
beneficial or detrimental effects on cardiovascular risk as the effect of the previously 
mentioned metabolic syndrome can be particularly deteriorating on the vasculature.  
 
Atherosclerotic vasculopathy occurs earlier and to a greater extent of severity in HIV 
patients and it seems to affect both the coronary and the larger vessels (Mary-
Krause M, 2003). Traditional risk factors such as family history, high LDL cholesterol, 
low HDL cholesterol, diabetes, hypertension and age > 55 also play a role in 
atherogenesis (Miller TL, 2013). 
Evidence suggests that HIV infection also leads to poor atherosclerotic outcomes in 
children and it is particularly interesting to study the routes of accelerated 
atherosclerosis in this population, as they will both live longer with the disease and 
be exposed to HAART for a longer period as well. Whilst HAART improves growth 
and lean-body mass and improves overall health in children, it also associates with 
Figure 2 - Mechanisms of HIV-associated atherosclerotic cardiovascular disease. Retrieved from (Lambert 
CT, 2016) 
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abnormalities in fat distribution in HIV-infected children. Both peripheral lipoatrophy 
and central obesity, otherwise known as lipodystrophy, occur in these children. 
Lipodystrophy is often, but not always, accompanied by metabolic disturbances, such 
as insulin resistance and dyslipidaemia. Up to 50% of HIV-infected children develop 
at some point lipodystrophy, especially with long-term exposure to NRTIs (European 
Paediatric Lipodystrophy Group, 2004). The mechanisms by which fat redistribution 
occurs in HIV-infected children are incompletely understood. The component of 
lipoatrophy is likely to be caused by mitochondrial DNA damage due to NRTI 
exposure, and possibly HIV infection itself, leading to respiratory chain dysfunction 
and decreased lipogenesis as well as increased fat apoptosis.  An increase in fat 
circulation and failure of hepatocytes and endothelial cells in removing circulating 
lipids efficiently is the possible cause of lipohypertrophy and dyslipidaemia. In 
children, there is evidence to suggest that a disturbance in insulin sensitivity and lipid 
metabolism may be mediated by low levels of adiponectin and HAART-induced 
adipocyte dysfunction (Barlow-Mosha L, 2013). Lipodystrophy seems to increase 
cardiovascular risk significantly, specifically in terms of premature atherosclerosis, in 
HIV-infected adults (Behrens GM, 2003). The relationship in children is still unclear. 
It seems that older HIV-infected children with long-term exposure to HAART have 
increased intima-media thickness (IMT) and decreased flow-mediated dilation (FMD) 
on ultrasound. These two biomarkers are excellent and relatively recent measures 
being used in assessing vascular anomalies as a way of evaluating CV risk. The 
former is a marker for atherosclerosis and seems to be dynamic as variations can 
occur with duration of treatment. Carotid intima-media thickness (cIMT) may regress 
or increase with prolonged treatment. Diminished flow-mediated dilation is a marker 
of poor endothelial function (Bonnet D, 2004).  The causes of structural and 
functional vascular changes in HIV-infected children are largely unknown and, as 
most data are from HAART-exposed children, it is not possible to differentiate 
between the effects of HIV infection and treatment.  However, a relationship has 
been found between PI therapies and higher cIMT and lower FMD in children 
(Charakida M, 2005).  	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4.	   Paediatric	   HIV	   Infection	   and	   Cardiovascular	  
Malignancies	  
Certain	  cardiovascular	  malignancies	  appear	  to	  have	  a	  higher	  incidence	  within	  the	  HIV-­‐positive	   population.	   Whilst	   there	   is	   not	   much	   information	   on	   paediatric	   incidence	   of	  these	  particular	  tumours,	  it	  is	  believed	  that	  they	  generally	  affect	  individuals	  in	  the	  later	  stages	  of	  disease	  (Miller TL, 2013).	  	  
The	   main	   primary	   cardiac	   malignancy	   associated	   with	   HIV	   infection	   is	   cardiac	  lymphoma.	   Lymphoma	   has	   an	   increased	   incidence	   in	   HIV-­‐infected	   populations	   and	  seems	   to	   be	   an	   AIDS-­‐defining	   illness.	   Non-­‐Hodgkin’s	   lymphoma	   is	   the	   most	   common	  type	   in	   this	   particular	   population	   and	   is	   believed	   to	   be	   26-­‐60	   times	  more	   common	   in	  HIV-­‐positive	  individuals	  when	  compared	  to	  HIV-­‐negative	  controls.	  They	  can	  present	  as	  the	   first	   manifestation	   of	   AIDS,	   leading	   up	   to	   diagnosis	   in	   up	   to	   4%	   of	   patients.	   The	  clinical	   picture	   is	   variable	   and	   some	   of	   the	   possible	   manifestations	   are	   chest	   pain,	  arrhythmias	  and	  signs	  heart	  failure	  on	  presentation.	  The	  prognosis	  is	  poor	  and	  cardiac	  lymphoma	   can	   rapidly	   progress	   to	   cardiac	   tamponade,	   myocardial	   infarction,	  conduction	  abnormalities	  and	  eventual	  heart	  failure	  (Miller TL, 2013).	  It	  seems	  that	  the	  implementation	   of	   HAART	   has	   not	   substantially	   affected	   the	   incidence	   of	   HIV-­‐related	  non-­‐Hodgkin’s	  lymphoma	  (Zoufaly A, 2009).	  	  
Kaposi’s	   sarcoma	   is	   a	   type	  of	   angiosarcoma	   that	  has	  been	   reported	   to	  affect	  primarily	  the	   cardiac	   tissue	   in	   HIV-­‐positive	   patients.	   In	   the	   early	   years	   of	   HIV	   history,	   Kaposi’s	  sarcoma	  affected	  around	  35%	  of	  HIV-­‐positive	  persons.	  There	  is	  an	  association	  between	  this	  tumour	  and	  herpes	  virus	  8.	  It	  affects	  endothelial	  cells	  and,	   in	  the	  heart	  it	  seems	  to	  have	  a	  preference	  for	  sub-­‐pericardial	  fat	  around	  the	  coronary	  arteries.	  Contrary	  to	  what	  has	   been	   said	   about	   HIV-­‐related	   Non	   Hodgkin’s	   lymphoma,	   HAART	   seems	   to	   have	  markedly	  decreased	  the	  incidence	  of	  Kaposi’s	  sarcoma	  (Fisher SD, 2011).	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5. HAART and Cardiovascular Risk 
HAART has improved immensely the longevity and quality of life of HIV-positive 
patients. Its relationship with CV risk in these patients is still in many parts unclear. 
Whilst in many ways it seems to control aspects of the disease that carry added CV 
risk, it has been also mentioned throughout this dissertation that in many cases 
HAART also seems to add risk on itself (Miller TL, 2013). Most the effects have been 
mentioned in-depth in the adequate sections. In this section a brief summarized 
presentation on the effect of HAART on CV risk will be made. 
HAART may start adding cardiovascular risk in utero as it is associated with 
increased incidence in cardiac anomalies in foetuses of HAART exposed HIV-
negative children who are born to HIV-positive mothers (Knapp KM, 2012).  In these 
cases, HAART seems to substantially affect the LV. Children have been found to 
have decreased LV wall thickness and mass on echocardiographies performed early 
on in life (Shearer WT, 2011).  
In HIV-positive children who are in use of HAART, certain aspects are also relevant. 
When it comes to heart anomalies, it seems that there is a higher incidence of low LV 
mass associated with overall smaller chambers. Drugs implicated on cardiac 
anomalies include abacavir, nelfinavir and nevirapine (Lipshultz SE, 2010). Changes 
occur during the first 10 years of exposure to therapy. In these children the effects 
are similar to the ones in foetuses exposed in utero as it seems that the 
consequences of HAART on the developing heart is transversal to both of these 
groups. Whilst some structural anomalies occur at an early age, it has been 
discussed that greater heart contractibility is found in the first years of life, in order to 
compensate of the smaller and structurally weaker heart. Mitochondrial toxicity has 
been found to block cardiac repair systems to damage and prevent adaptations such 
as hypertrophy and hyperplasia in the heart of an HIV-positive HAART treated child 
(Mas CM, 2012).  Specifically, NRTIs have been associated with altered 
mitochondrial DNA replication and cardiac structure. It not yet clear whether altered 
mitochondrial DNA replication is the cause of cardiomyopathy, but in some patients, 
suspension of specific NRTI drugs may improve LV dysfunction (Fisher SD, 2011).  
Altered body composition and hyperlipidaemia are associated with some PIs, but 
theses lipid abnormalities vary with different drugs in the class (Dapena M, 2012). 
Ritonavir seems to have a stronger effect on lipid metabolism, with a mean increase 
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of total cholesterol concentration of 2.0 mmol/L and a mean increase in triglyceride 
concentration of 1.83 mmol/L. PIs also increased lipoprotein a in patients with 
elevated pre-treatment values. The overall effects of PIs on the lipid metabolism 
present an increased risk for atherosclerotic cardiovascular disease (Worm SW, 
2010). NRTIs have also been discussed to confer metabolic alterations and increase 
CV risk (Dapena M, 2012).  Control of lipid metabolic anomalies is important and 
measures such as low-level aerobic exercise and switching drugs may reverse both 
triglyceride concentrations and abnormal fat deposition (Fisher SD, 2011).   
PIs may cause endothelial dysfunction through several mechanisms, such as 
reduced nitric oxide production, reduced expression of nitric oxide synthase and 
increased formation of reactive oxygen species (Mas CM, 2012). These effects don’t 
appear to be transversal to the whole class, as some specific drugs decrease 
endothelial function and others actually improve it (Dube MP, 2008). 
An estimated 60% increase in hospitalizations due to strokes in HIV-infected persons 
has been attributed to HAART use. Several drugs appear to promote atherosclerosis. 
It is still unclear which exact mechanisms confer this increased risk but one of the 
hypotheses is the increase in life expectancy in HIV patients (Ovbiagele B, 2011).  
Whilst this hypothesis may contribute, it is quite clear that it doesn’t work on its own. 
HIV-infected children who are treated with HAART are at risk for accelerated 
atherosclerosis. A conjunction of metabolic anomalies and actual structural changes 
to the vasculature seem relevant. These structural changes are reflected by an 
increased cIMT and lower FMD (Charakida M, 2005). PIs have been associated with 
these changes both in children and adults (Lorenz MW, 2008). Heightened cIMT 
raises concern for premature atherosclerosis in HAART-treated patients (Ordovas K, 
2012).  	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Table 1 - Cardiac effects of antiretroviral drugs. Based on Mas CM, 2012. 
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6. Conclusion 
HIV infection has significant effects on the cardiovascular system. In children, in 
particular, given their significant longevity and longer expected exposure to HAART 
when compared to the infected adult population, the issue of long-term risk is a 
priority.  In economically developed countries, where HAART is easily accessible, 
viral load control is nowadays not the main concern of physicians. Therapy is 
extremely effective in diminishing viral replication to levels almost undetectable. Due 
to this achievement, infectious complications became less prevalent and the mortality 
associated to these complications has reduced significantly. As such, HIV-infected 
children are living longer lives. Other complications arose from this new life 
expectancy. Cardiovascular risk has become one of the main areas of concern.  
Infected children are foreseen to suffer alterations in the heart, which manifest early 
in childhood, and on the vasculature. Studies have demonstrated that both the viral 
infection itself and the use of HAART cause added CV risk in these patients. When it 
comes to the underlying mechanisms, much is still poorly understood. Whilst some 
drugs included in HAART lead to alterations such as metabolic syndrome and 
accelerated atherosclerosis, the use of this therapy is still of great importance. Not 
only is HAART the main pillar in keeping these patients alive when it comes to viral 
control, but it also has a role when it comes to reducing certain cardiovascular 
complications. In no way does the CV risk added by HAART counteract all the 
benefits its use brings. 
As HIV-positive children have added CV risk, control of traditional CV risk factors and 
monitoring of both cardiovascular and metabolic systems are of extreme importance. 
Lipid profile, ECG and echocardiogram can be used as a way of screening. Newer 
parameters used as biomarkers mainly in evaluating vascular risk, such as cIMT and 
FMD are promising as early markers of disease.  
It is important to point out that current evidence on HIV infection and CV risk largely 
stems from research in adults. Modes of infection, immune maturity, growth and 
development and treatment are, however, in many ways different in children. As 
such, more in-depth paediatric research, which accounts for the interaction between 
normal growth and development, HIV infection and HAART is of great importance.  	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